Kailera and Alamar are leading a resurgence in biotech IPOs after a period of investor drought in the life sciences sector
Strong market demand for GLP-1 drugs is driving renewed investor confidence in biotech companies
Next-generation diagnostic testing platforms are attracting significant capital despite AI companies capturing the majority of venture dollars
The shift signals a diversification of venture investment away from AI-focused companies back into healthcare innovation
Ask the AI about this article →
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
CrowdStrike Holdings Inc
ASE Technology CEO and SEMI Global Board Executive Committee Chair Tien Wu said AI's early-stage growth is cre…
Fervo Energy signed a deal to supply 396 MW of electricity from its Cape Station project in Utah to a Google d…
Nvidia co-announced with Vertiv in August that it is making progress on 800-volt power infrastructure for its…
John Ternus takes over as CEO of Apple today, stepping into the role as the company confronts the AI era
Top AI-native open source projects like Flue and tldraw are refusing external pull requests, often because the…
